α-NETA是一种非竞争性的胆碱乙酰转移酶（ChAT；IC50=9μM）抑制剂。
Cas No.:115066-04-1
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
α-NETA is a non-competitive inhibitor of choline acetyltransferase (ChAT; IC50=9μM). α-NETA inhibits ALDH1A1 (IC50=0.04μM) and antagonizes the activity of chemokine-like receptor 1 (CMKLR1), cholinesterase (ChE; IC50=84μM), and acetylcholinesterase (AChE; IC50=300μM). α-NETA can be used in research related to cancer and diabetic nephropathy[1-4].
In vitro, α-NETA (5μM) pretreated human gastric cancer AGS cells for 16-24 hours. α-NETA inhibited Chemerin-induced cell migration and invasion and suppressed cell morphological transformation[5]. α-NETA (3μM) treated chemerin-overexpressing human trophoblast cells (HTR8/SVneo) for 24-48 hours. α-NETA induced cell membrane rupture, cytoplasmic leakage, and activated the GSDMD/caspase-4-mediated pyroptosis pathway by increasing the expression of caspase-4 and GSDMD and the secretion of IL-18[6].
In vivo, α-NETA (30mg/kg; once daily) was administered by gavage to high-fat diet-induced obese C57BL/6 mice for 4 weeks. α-NETA reduced body weight in the mice[7]. α-NETA (10mg/kg; three times per week) was administered via intraperitoneal injection to nude mice bearing UOK101 cell xenograft tumors and SCID mice bearing human ccRCC PDX (UTSW-XP296) models (subcutaneous and orthotopic implantation) for 70 days. α-NETA significantly inhibited tumor growth and reduced lipid deposition within the tumors, while no significant changes in animal health status were observed[8].
References:
[1] Sastry BV, Jaiswal N, Janson V, et al. Relationships between chemical structure and inhibition of choline acetyltransferase by 2-(alpha-naphthoyl)ethyltrimethylammonium and related compounds. Pharmacol Res Commun. 1988 Sep;20(9):751-71.
[2] Graham KL, Zhang JV, Lewén S, et al. A novel CMKLR1 small molecule antagonist suppresses CNS autoimmune inflammatory disease. PLoS One. 2014 Dec 1;9(12):e112925.
[3] Qiao L, Wu X, Zhang J, et al. α-NETA induces pyroptosis of epithelial ovarian cancer cells through the GSDMD/caspase-4 pathway. FASEB J. 2019 Nov;33(11):12760-12767.
[4] Aleksandrov AA, Polyakova NV, Vinogradova EP, et al. The TAAR5 agonist α-NETA causes dyskinesia in mice. Neurosci Lett. 2019 Jun 21;704:208-211.
[5] Kumar JD, Aolymat I, Tiszlavicz L, et al. Chemerin acts via CMKLR1 and GPR1 to stimulate migration and invasion of gastric cancer cells: putative role of decreased TIMP-1 and TIMP-2. Oncotarget. 2019 Jan 4;10(2):98-112.
[6] Tan L, Chen Z, Sun F, et al. Placental trophoblast-specific overexpression of chemerin induces preeclampsia-like symptoms. Clin Sci (Lond). 2022 Feb 25;136(4):257-272.
[7] Zheng C, Zheng Y, Chen X, et al. α-NETA down-regulates CMKLR1 mRNA expression in ileum and prevents body weight gains collaborating with ERK inhibitor PD98059 in turn to alleviate hepatic steatosis in HFD-induced obese mice but no impact on ileal mucosal integrity and steatohepatitis progression. BMC Endocr Disord. 2023 Jan 10;23(1):9.
[8] Wang D, Mahmud I, Thakur VS, et al. GPR1 and CMKLR1 Control Lipid Metabolism to Support the Development of Clear Cell Renal Cell Carcinoma. Cancer Res. 2024 Jul 2;84(13):2141-2154.
α-NETA是一种非竞争性的胆碱乙酰转移酶（ChAT；IC50=9μM）抑制剂。α-NETA可抑制ALDH1A1（IC50=0.04μM）和拮抗趋化因子样受体1（CMKLR1）、胆碱酯酶（ChE；IC50=84μM）和乙酰胆碱酯（AChE；IC50=300μM）活性。α-NETA可用于癌症和糖尿病肾病的相关研究[1-4]。
在体外，α-NETA（5μM）预处理人胃癌AGS细胞16-24小时。α-NETA可抑制Chemerin诱导的细胞迁移与侵袭，并抑制细胞形态转化[5]。α-NETA（3μM）处理过表达chemerin的人滋养细胞（HTR8/SVneo）24-48小时。α-NETA诱导细胞膜破裂、胞质泄漏，并通过增加caspase-4和GSDMD的表达及IL-18的分泌，激活了GSDMD/caspase-4介导的细胞焦亡通路[6]。
在体内，α-NETA（30mg/kg；每天一次）灌胃于高脂饮食诱导的肥胖C57BL/6小鼠4周。α-NETA降低了小鼠的体重[7]。α-NETA（10mg/kg；每周三次）腹腔注射于携带UOK101细胞异种移植瘤的裸鼠70天，以及携带人ccRCC PDX（UTSW-XP296）的SCID小鼠（皮下及原位植入模型）。α-NETA显著抑制了肿瘤生长，并减少了肿瘤中的脂质沉积，同时未观察到动物健康状况的显著变化[8]。
| Cell experiment [1]: | |
Cell lines | HTR8/SVneo cells (immortalized human trophoblast cells) |
Preparation Method | HTR8/SVneo cells were maintained in DMEM/F12 medium supplemented with 10% fetal bovine serum (FBS) at 37°C with 5% CO₂. Cells were infected with LV-hChemerin-GFP lentivirus to overexpress chemerin, selected with puromycin, and subsequently exposed to either 1% DMSO (vehicle control) or 3μM α-NETA dissolved in DMSO. |
Reaction Conditions | 3μM; 24-48h |
Applications | α-NETA prevented the inhibitory effects of chemerin overexpression on cell migration, invasion, and tube formation in co-culture with human umbilical vein endothelial cells (HUVECs). |
| Animal experiment [2]: | |
Animal models | C57BL/6 mice (male, 8-10 weeks old) |
Preparation Method | Mice were fed a high-fat diet (HFD, 40 kcal% fat, 2% fructose) for 12 weeks to induce obesity. Then, mice in the α-NETA group received daily treatments of α-NETA (30mg/kg) via gavage for 4 weeks. Mice in the α-NETA+PD group received daily treatment of α-NETA plus PD98059 (0.3mg/kg via tail vein injection). At the end of intervention, mice were sacrificed for analysis of body weight, liver histology, ileal CMKLR1 mRNA, and serum parameters. |
Dosage form | 30mg/kg; daily gavage; for 4 weeks |
Applications | α-NETA reduced body weight gain in HFD-induced obese mice. Combined with PD98059, α-NETA further reduced body weight and alleviated hepatic steatosis. α-NETA down-regulated CMKLR1 mRNA expression in ileum. No impact on ileal ZO-1 or pERK protein expression, and no significant changes in serum endotoxin levels. |
References: | |
| Cas No. | 115066-04-1 | SDF | |
| 别名 | 2-(BETA-萘甲酰基)乙基三甲基碘化铵 | ||
| Canonical SMILES | O=C(CC[N+](C)(C)C)C1=CC2=CC=CC=C2C=C1.[I-] | ||
| 分子式 | C16H20NO•I | 分子量 | 369.2 |
| 溶解度 | DMSO: 3mg/ml,Methanol: Soluble | 储存条件 | Store at -20°C, protect from light, stored under nitrogen |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.7086 mL | 13.5428 mL | 27.0856 mL |
| 5 mM | 541.7 μL | 2.7086 mL | 5.4171 mL |
| 10 mM | 270.9 μL | 1.3543 mL | 2.7086 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet